Background/Aims Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring hepatitis B core-related antigen (HBcrAg) after NA cessation may stratify the risk of subsequent clinical relapse (CR).
Methods This retrospective multicenter analysis enrolled adults with CHB who were prospectively monitored after discontinuing entecavir or tenofovir with negative HBeAg and undetectable HBV DNA at the end of treatment (EOT). Patients with cirrhosis or malignancy were excluded. CR was defined as serum alanine aminotransferase > two times the upper limit of normal with recurrent viremia. We applied time-dependent Cox proportional hazard models to clarify the association between HBcrAg levels and subsequent CR.
Results The cohort included 203 patients (median age, 49.8 years; 76.8% male; 60.6% entecavir) who had been treated for a median of 36.9 months (interquartile range [IQR], 36.5–40.1). During a median post-treatment follow-up of 31.7 months (IQR, 16.7–67.1), CR occurred in 104 patients with a 5-year cumulative incidence of 54.8% (95% confidence interval [CI], 47.1–62.4%). Time-varying HBcrAg level was a significant risk factor for subsequent CR (adjusted hazard ratio [aHR], 1.53 per log U/mL; 95% CI, 1.12–2.08) with adjustment for EOT HBsAg, EOT anti-HBe, EOT HBcrAg and time-varying HBsAg. During follow-up, HBcrAg <1,000 U/mL predicted a lower risk of CR (aHR, 0.41; 95% CI, 0.21–0.81).
Conclusions Dynamic measurement of HBcrAg after NA cessation is predictive of subsequent CR and may be useful to guide post-treatment monitoring.
Citations
Citations to this article as recorded by
Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial Rong Fan, Rui Deng, Qing Xie, Fang Wang, Xieer Liang, Hong Ma, Huiying Rao, Yanhang Gao, Chunxiu Zhong, Qing Guo, Sheng Shen, Ya Xu, Xingyu Lu, Hongbo Gao, Honglian Bai, Xiaoguang Dou, Jian Sun Clinical Gastroenterology and Hepatology.2026; 24(6): 1611. CrossRef
Similar hepatic outcome by SGLT2i vs. DPP4i for at-risk cohort with CHB & T2DM: A nationwide target trial emulation study Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon Annals of Hepatology.2026; 31(1): 102175. CrossRef
Mitochondrial metabolic remodeling predicts therapeutic response to PegIFN-α in chronic hepatitis B Yingying Zhang, Xiu Han, Chengyu Xu, Yahui Song, Jinghan Zhu, Ruoran Zhou, Yiling Chen, Mingming Liu, Junchi Xu, Xiangwei Wu, Qingzhen Han, Zutao Chen Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Risk factors and predicted model for clinical relapse after antiviral therapy cessation in chronic hepatitis B patients: a retrospective real-world data analysis Xiaoli Zhang, Meiyan Mao, Yunxia Zhang, Xiuxi Li BioMedical Engineering OnLine.2026;[Epub] CrossRef
Clinical utility of hepatitis B core-related antigen in chronic hepatitis B infection: diagnostic, prognostic, and therapeutic implications Bukhari Isah Shuaib, Usman Linda Itunu, Aminat Daud Egyptian Liver Journal.2026;[Epub] CrossRef
Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss Ying‐Nan Tsai, Jia‐Ling Wu, Cheng‐Hao Tseng, Tzu‐Haw Chen, Ying‐Chu Chung, Mindie H. Nguyen, Jaw‐Town Lin, Katsuya Nagaoka, Yasuhito Tanaka, Yao‐Chun Hsu Alimentary Pharmacology & Therapeutics.2026; 64(1): 89. CrossRef
Low-level hepatitis B surface antigen by ECLIA stratifies early relapse risk in patients with interferon-based HBV functional cure Xiangyong Li, Baoer Wu, Huaping Xie, Hao Hu, Ting Liu, Xu You, Yanhua Bi, Yurong Gu Frontiers in Immunology.2026;[Epub] CrossRef
Hepatitis B core-related antigen as a multifaceted biomarker in chronic hepatitis B: implications for immune activity and hepatocellular carcinoma prediction Kwon Yong Tak, Seok Hwan Kim, Myeong Jun Song The Korean Journal of Internal Medicine.2026; 41(4): 636. CrossRef
Early HBcrAg and Anti‐HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials Edo J. Dongelmans, Jordan J. Feld, André Boonstra, Sylvia M. Brakenhoff, David Wong, Colina Yim, Mark Claassen, Pieter Honkoop, Bettina E. Hansen, Robert A. de Man, Scott Fung, Thomas Berg, Florian van Bömmel, Harry L. A. Janssen, Milan J. Sonneveld Alimentary Pharmacology & Therapeutics.2025; 61(3): 570. CrossRef
Achieving chronic hepatitis B functional cure: Factors and potential mechanisms Jiarui Zheng, Zilong Wang, Linxiang Huang, Zixuan Qiu, Yandi Xie, Suzhen Jiang, Bo Feng Virus Research.2025; 351: 199507. CrossRef
Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure Yue Qiu, Qiao Tang, Xiao-Qing Liu, Yun-Ling Xue, Yi Zeng, Peng Hu World Journal of Hepatology.2025;[Epub] CrossRef
Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon Liver International.2025;[Epub] CrossRef
Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study Yong-Hong Wang, Ya-Chao Tao, Meng-Lan Wang, Cheng-Run Song, Jiang-Nan Peng, En-Qiang Chen Journal of Virus Eradication.2025; 11(4): 100617. CrossRef
Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen Yoshihiko Yano, Itsuko Sato, Takamitsu Imanishi, Ryutaro Yoshida, Takanori Matsuura, Yoshihide Ueda, Yuzo Kodama Diagnostics.2024; 14(7): 728. CrossRef
Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation” Yun-Fan Liaw Clinical and Molecular Hepatology.2024; 30(2): 269. CrossRef
Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen Chen-Te Huang, Tai-Chung Tseng Clinical and Molecular Hepatology.2024; 30(2): 154. CrossRef
Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu Clinical and Molecular Hepatology.2024; 30(2): 276. CrossRef
Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu Clinical and Molecular Hepatology.2024; 30(2): 293. CrossRef
A critical review of diagnostic and prognostic markers of chronic hepatitis B infection Shuaibu Abdullahi Hudu, Sa’adatu Haruna Shinkafi, Abdulgafar Olayiwola Jimoh Medical Review.2024; 4(3): 225. CrossRef
Virological markers for clinical trials in chronic viral hepatitis Jean-Michel Pawlotsky JHEP Reports.2024; 6(11): 101214. CrossRef
First
Prev
